<DOC>
	<DOCNO>NCT01440920</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability OCV-501 patient acute myeloid leukemia ( AML ) achieve complete remission induction regimen complete standard consolidation therapy .</brief_summary>
	<brief_title>A Phase I Study OCV-501 Acute Myeloid Leukemia Patients</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Key Patients acute myeloid leukemia include patient secondary leukemia . However , patient MDS apparently evolve itno AML patient AML accompany ( 15 ; 17 ) ( q22 ; q12 ) , ( PML/RARalpha ) , exclude . Patients achieve first complete remission induction regimen finish standard consolidation therapy . Age : â‰¥ 60years age ( time signature inform consent form ) Sex : Male Female Patients capable give informed consent Patient 's blast cell show expression WT1mRNA , detect quantitative RTPCR . Patients must one follow HLA DRB1 type : HLADRB1*01:01 , *04:05 , *15:01 , *15:02 , *08:03 *09:01 . Key Patients schedule bone marrow transplantation Patients administer exceeded acceptable therapeutic dose immunosuppressant adrenal cortical steroid . Patients uncontrollable active infectious disease Patients autoimmune disease ( include Hashimoto 's disease , idiopathic thrombocytopenic purpura , autoimmune hepatitis ) medical history active autoimmune disease Immunocompetent patient Patients complication interstitial pneumonia medical history interstitial pneumonia</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Acute myeloid leukemia</keyword>
	<keyword>WT1</keyword>
</DOC>